Trial Profile
A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs F-18 fluorothymidine (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Diagnostic use
- Sponsors Merck Sharp & Dohme Corp.
- 29 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Dec 2011 Actual patient number is 45 as reported by ClinicalTrials.gov.
- 10 Nov 2011 Planned end date changed from 1 Nov 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.